Hester Biosciences Limited reported a sharp rise in earnings for the financial year ending March 2026, with consolidated net profit climbing 99% year-on-year to Rs. 57.48 crore, supported by stronger demand in its poultry healthcare business and improved operational efficiency.
Revenue from operations rose 7% to Rs. 332.60 crore, compared with Rs. 311.10 crore in FY25. EBITDA increased 53% to Rs. 105.65 crore, while EBITDA margins improved to 32% from 22% a year earlier.
The company’s board recommended a dividend of Rs. 11 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
Performance in the January-March quarter was particularly strong. Net profit for Q4FY26 surged to Rs. 16.55 crore from Rs. 1.54 crore in the same period last year, marking a rise of 974%. Quarterly revenue increased 22% to Rs. 100.11 crore.
Quarterly EBITDA stood at Rs. 36.10 crore, up 167% year-on-year, with margins expanding to 36% from 17% in Q4FY25.
The Ahmedabad-based animal healthcare company said earnings growth was driven by a stronger contribution from its Poultry Healthcare Division, an improved product mix and ongoing cost optimisation measures. The company also cited tighter working capital management and operational discipline as key contributors to profitability.
During the quarter, Hester Biosciences capitalised its BSL-3 facility as part of broader capacity expansion and infrastructure strengthening plans. The company said it is also optimising parts of its manufacturing infrastructure to improve utilisation efficiency and reduce operating costs.
In another development, the company received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine, further expanding its poultry vaccine portfolio amid growing demand for animal health products in India’s poultry sector.
